Related Experiment Video
Updated: Jul 27, 2025

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
Epigenetic suppression of PGC1α (PPARGC1A) causes collateral sensitivity to HMGCR-inhibitors within BRAF-treatment
Jiaxin Liang1,2, Deyang Yu1,2, Chi Luo1,2,3
1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Abstract:
While targeted treatment against BRAF(V600E) improve survival for melanoma patients, many will see their cancer recur. Here we provide data indicating that epigenetic suppression of PGC1α defines an aggressive subset of chronic BRAF-inhibitor treated melanomas. A metabolism-centered pharmacological screen further identifies statins (HMGCR inhibitors) as a collateral vulnerability within PGC1α-suppressed BRAF-inhibitor resistant melanomas. Lower PGC1α levels mechanistically causes reduced RAB6B and RAB27A expression, whereby their combined re-expression reverses statin vulnerability. BRAF-inhibitor resistant cells with reduced PGC1α have increased integrin-FAK signaling and improved extracellular matrix detached survival cues that helps explain their increased metastatic ability. Statin treatment blocks cell growth by lowering RAB6B and RAB27A prenylation that reduces their membrane association and affects integrin localization and downstream signaling required for growth. These results suggest that chronic adaptation to BRAF-targeted treatments drive novel collateral metabolic vulnerabilities, and that HMGCR inhibitors may offer a strategy to treat melanomas recurring with suppressed PGC1α expression.
Insights
Targeted BRAF therapy resistance in melanoma can be linked to suppressed PGC1α. Statins, a type of HMGCR inhibitor, show promise in treating these aggressive, recurring melanomas by targeting metabolic vulnerabilities.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Targeted BRAF(V600E) therapies improve melanoma survival but acquired resistance leads to recurrence.
- Epigenetic suppression of PGC1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) is associated with aggressive, treatment-resistant melanomas.
Purpose of the Study:
- To investigate the role of PGC1α suppression in BRAF-inhibitor resistant melanoma.
- To identify pharmacological vulnerabilities in PGC1α-suppressed melanoma.
- To evaluate statins as a potential treatment strategy for recurrent melanoma.
Main Methods:
- Metabolism-centered pharmacological screening to identify drug sensitivities in PGC1α-suppressed melanoma cells.
- Analysis of gene expression (RAB6B, RAB27A) and protein prenylation.
- Assessment of integrin-FAK signaling and extracellular matrix interactions.
Main Results:
- Epigenetic suppression of PGC1α defines an aggressive subset of BRAF-inhibitor resistant melanomas.
- Statins (HMGCR inhibitors) represent a collateral vulnerability in these resistant melanomas.
- Reduced PGC1α leads to decreased RAB6B and RAB27A expression, increased integrin-FAK signaling, and enhanced metastatic potential; statin treatment reverses this by inhibiting prenylation.
Conclusions:
- Chronic adaptation to BRAF-targeted therapies induces novel metabolic vulnerabilities in melanoma.
- HMGCR inhibitors (statins) may offer a therapeutic strategy for melanomas with suppressed PGC1α.
- Re-expression of RAB6B and RAB27A can reverse statin sensitivity, highlighting a potential resistance mechanism.
Related Concept Videos
Abnormal Proliferation
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Epigenetic Regulation
X-chromosome...
GPCR Desensitization
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Induced Pluripotent Stem Cells
Somatic...

